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Abstract
Background: Asymptomatic female genital tuberculosis can impair tubal and endometrial function and later
present as subfertility. A majority of the patients with genital tuberculosis in endemic regions present with
subfertility and the delay in presentation, coupled with the potential the disease has in mimicking other
gynecological conditions, renders it elusive. In addition to the challenge of diagnosing genital tuberculosis, fertility
outcomes after treatment are not impressive. This is particularly so in the background of another confounding
subfertility factor to which interventional efforts may initially be directed, at the expense of undiagnosed genital
tuberculosis. We therefore present a case of subfertility due to endometrial tuberculosis, but confounded by other
subfertility factors notably polycystic ovary syndrome. To the best of our knowledge this case report is the first of its
kind in the literature.
Case presentation: This is a case report of a 42-year-old woman of African descent who presented to our fertility
clinic with a 10-year history of primary subfertility and amenorrhea of 6 years duration. She was a nurse in a
medical ward and had no prior history of tuberculosis. She had undergone a diagnostic laparoscopy 8 years prior
which demonstrated dense pelvic adhesions and an impression of tubal factor subfertility was made. At
presentation, her gonadal hormone profile and pelvic ultrasound were consistent with polycystic ovary syndrome. A
negative response to a progesterone challenge test prompted a hysteroscopic evaluation which revealed
endometrial atrophy. Endometrial biopsies confirmed histological features consistent with tuberculosis. Normal
endometrial function was not restored despite adequate treatment and her options were limited to surrogacy or
adoption.
Conclusions: Genital tuberculosis is elusive in presentation and clinicians should consider it in patients with
amenorrhea and/or tubal disease from tuberculosis-endemic regions. Due to the attendant high cost of fertility
treatment and associated poor fertility outcomes, it is prudent to explore options to diagnose it early. A routine
endometrial biopsy in a patient with subfertility in a tuberculosis-endemic area would be pragmatic. An alternative
algorithm in management would be risk stratification prior to endometrial biopsy.
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Background
The exact incidence of female genital tuberculosis
(TB) is difficult to ascertain given the quiescent nature
of the disease and the varied diagnostic methods. Sub-
fertility might be the only symptom of genital TB and
is associated with tubal damage in a majority of cases
[1]. Hematogenous spread is thought to be the process
by which the tubercle bacilli implant into the mucosa
of the fallopian tubes and subsequently affect the
endometrium by direct extension [2].
Diagnosis of female genital TB requires a high index
of suspicion due to its asymptomatic nature and the high
probability of the disease mimicking other gynecological
conditions [3]. In addition to the diagnostic challenge,
fertility outcomes after treatment are not impressive [4]
particularly in the background of another factor causing
subfertility. A diagnostic hysteroscopy and endometrial
biopsy that are often necessary to arrive at a diagnosis
are not without challenges of accessibility and cost in
TB-endemic regions. The coexistence of genital TB with
other gynecological conditions such as polycystic ovary
syndrome (PCOS) leads to a delay in diagnosis and com-
pounds the challenges in treatment of subfertility. The
objective of this case report is to highlight the challenges
in diagnosis and management of genital TB, particularly
in the background of other subfertility factors, and to
consider pragmatic approaches in the treatment of sub-
fertility in TB-endemic areas.
Case presentation
We present a report of a 42-year-old woman of African
descent who presented to our fertility clinic with a 10-year
history of primary subfertility and amenorrhea of 6 years
duration. She was a nurse in a medical ward and had no
prior history of TB. She was separated from her husband
and intended to use donated sperm for her assisted
conception treatment. The timeline of interventions is
summarized in Table 1 below.
The initial evaluation for subfertility (in a different in-
stitution) included a diagnostic laparoscopy performed
8 years prior. The laparoscopy had revealed dense pelvic
adhesions (“a frozen pelvis”), and an impression of tubal
factor subfertility was made. It appears that there was no
deliberate attempt to make a definitive diagnosis as to
the cause of the tubal disease as no tissue samples or
swabs were assessed. She had undergone a pelvic ultra-
sound scan which was reported as normal and had had a
negative pap smear. There were neither further details of
this prior evaluation nor a detailed summary from her
previous gynecologist.
She neither had a history of pelvic pain nor a history sug-
gestive of previous sexually transmitted infections. She did
not report any symptoms suggestive of TB, notably fever,
night sweats, or weight loss. She weighed 84 kg, was
1.58 meters tall with a body mass index (BMI) of 33. Her
blood pressure was 140/90 mmHg and her clinical examin-
ation was essentially normal. She had no lymphadenopathy,
acne, or hirsutism. Her gonadal hormone profile presented
in Table 2 was in keeping with PCOS.
The initial high estradiol (E2) levels and the biochemical
evidence of PCOS prompted the use of an exogenous pro-
gestogen to initiate endometrial shedding prior to baseline
ultrasound scan in preparation for an in vitro fertilization
(IVF) cycle. She received medroxyprogesterone (Provera)
10 mg orally once a day for 5 days but had no withdrawal
bleed. Two weeks after administration of medroxyproges-
terone, she still reported no withdrawal bleed. A subse-
quent pelvic ultrasound scan showed normal uterine
morphology. Her endometrial thickness was 3 mm with a
small amount of endometrial fluid with no focal endomet-
rial pathology demonstrable on ultrasound. Her ovaries
had a polycystic appearance with multiple small peripheral
follicles. A simple cyst of 4 cm in size was visualized in
her right ovary. The ultrasound findings further supported
the diagnosis of PCOS.
Endometrial assessment by hysteroscopy was under-
taken in view of the presence of endometrial fluid and the
negative progesterone challenge test. Hysteroscopy re-
vealed an atrophic endometrium interspersed with areas




2004 33 Diagnostic laparoscopy revealing dense pelvic
adhesions
2006 35 Onset of amenorrhea
2012 41 Gonadal profile: elevated E2, high AMH for age
(5.18 ng/ml).
Progesterone challenge test: no withdrawal bleed.
Ultrasound: polycystic ovaries, endometrial fluid,
ET 3 mm
2013 42 Hysteroscopy and endometrial biopsy: TB
endometritis.
2013 42 Started anti-TB treatment
Completed anti-TB antibiotics. No menses
Administration of COC: no menses
AMH anti-Müllerian hormone, COC combined oral contraceptives, E2 estradiol,
ET endometrial thickness, TB tuberculosis
Table 2 Gonadal hormone profile
Investigation Result
17 beta estradiol 3447 (99–452) pmol/L
Total testosterone 5.2 (0.52–2.4) nmol/L
Follicle-stimulating hormone (FSH) 6.6 (1.0–8.8) IU/L
Luteinizing hormone (LH) 38.4 (1–18) IU/L
Prolactin 0.45 (0.09–1.26) nmol/L
Anti-Müllerian hormone 37.00 pmol/L (elevated for age)
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of thickened endometrium, with no synechiae, and bilat-
erally obliterated and poorly visualized tubal ostia. Di-
rected endometrial biopsies were taken. Histology showed
endometrial tissue with a normal gland to stromal ratio.
Numerous granulomas, with epithelioid histiocytes,
plasma cells and Langhans giant cells were visualized in
the stroma with some areas of necrosis. A Ziehl–Neelsen
stain was negative. A conclusion of granulomatous endo-
metritis possibly TB endometritis was made.
Following the diagnosis of TB, further investigations were
carried out. A chest X-ray was normal and an HIV test was
negative. Her liver function tests, creatinine, and full blood
count were all normal. She was referred to a physician for
TB treatment and plans for assisted reproductive technol-
ogy (ART) were deferred. Treatment for TB endometritis
was started by use of a 6-month regimen of antitubercular
therapy. An initial 2-month intensive phase of four drugs
(rifampicin 600 mg once daily, isoniazid 300 mg once daily,
pyrazinamide 2000 mg once daily, and ethambutol
1600 mg once daily) was followed by a 4-month course of
two drugs (rifampicin 600 mg once daily, isoniazid 300 mg
once daily). In addition, a daily dose of pyridoxine 25 mg
was administered throughout the 6 months. Antihyperten-
sive treatment was initiated in the second month of antitu-
bercular treatment. She was evaluated after a week of
initiation of TB therapy and thereafter every month by the
physician. She was compliant on all her medications and
experienced no adverse effects. She reported no menses
despite completing the TB treatment. The supervising TB
physician did not consider it clinically relevant to re-biopsy
after a full course of TB therapy.
She maintained her desire for conception and revisited
the fertility clinic. A follow-up ultrasound scan showed
less evident endometrial fluid compared to the initial
pelvic ultrasound scan with an endometrial thickness of
3.7 mm. Her ovaries were still polycystic but the 4 cm
right ovarian cyst was no longer present. A decision on a
second trial of endometrial stimulation/shedding was
made. She received one cycle of low-dose combined oral
contraceptive pills but reported no menses. There was
no change in endometrial findings on follow-up scan.
A conclusion of endometrial scarring post-endometrial
TB was made. Further attempts at endometrial stimulation
were discouraged in view of her very high endogenous E2
and complete failure of response to exogenous steroids.
The options of surrogacy or adoption were discussed while
further ART interventions were discouraged due to the
endometrial damage.
Discussion
The limitations in management of this case were primarily
a delay in definitive diagnosis and treatment. This could
have had a compounding effect on our patient’s fertility in
that not only did tubal and endometrial damage ensue but
also allowed an age-related decrease in ovarian function, a
factor noted to be the most significant as regards fertility
outcomes in IVF [5]. It remains open to discussion if an
earlier diagnosis and treatment of the genital TB may have
made a difference in her reproductive outcomes following
ART. Of note, however, a possible risk factor that the pa-
tient had was her profession which potentially could have
exposed her to TB.
This case highlights the need for prompt and efficient
referrals in patient management. Sufficient details were
unavailable upon referral including details of the initial
diagnostic laparoscopy that had demonstrated tubal disease.
In addition, health care costs were a significant constraint
for this patient, which demonstrates the challenges of fertil-
ity treatment particularly in resource-limited settings.
Following failure of resumption of endometrial func-
tion, the patient went into denial. She continued to visit
the fertility clinic occasionally, inquiring about the possi-
bility of new interventions. She remains hopeful that
endometrial function will resume prior to menopause.
She still desires to carry her own pregnancy and is not
keen on surrogacy with her own oocytes. It is important
to highlight that patients presenting with subfertility re-
quire psychosocial support at every step of management.
Conclusions
This original case report seeks to inform all clinicians,
particularly those in reproductive medicine, that genital
TB is a diagnosis that requires a high index of suspicion
to diagnose especially when the patient’s history and
clinical examination is not suggestive of the disease [3].
Its elusive nature and tendency to mimic other
gynecological conditions can lead to delay in diagnosis. Oc-
casionally, some patients present with subfertility and their
fertility treatment options become limited particularly those
with endometrial damage. Given the elusive nature of geni-
tal TB and the high cost of fertility treatment, it is prudent
to explore options to diagnose it early. Despite it being diffi-
cult to ascertain to what extent a routine endometrial bi-
opsy in a patient with subfertility is beneficial, some fertility
centers in TB-endemic areas consider this approach to be
pragmatic for all patients presenting with subfertility [6].
An alternative algorithm in management would be risk
stratification prior to endometrial biopsy.
Abbreviations
ART, assisted reproductive technology; E2, estradiol; IVF, in vitro fertilization;
PCOS, polycystic ovary syndrome; TB, tuberculosis
Acknowledgements
We would like to acknowledge the patient on whom this case report is
based.
No external funding was sourced for this case report.
Mariara et al. Journal of Medical Case Reports  (2016) 10:168 Page 3 of 4
Authors’ contributions
AM and PW were involved in the clinical management of the patient and
were major contributors in the writing of the manuscript. AK and CM
analyzed and interpreted the patient data regarding subfertility, conducted
the literature review, and drafted the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent
Written informed consent was obtained from the patient for publication of
this case report. A copy of the written consent is available for review by the
Editor-in-Chief of this journal.
Author details
1AIC Kijabe Hospital, P.O Box 20-00220, Kijabe, Kenya. 2Aga Khan University
Hospital, 3rd Parklands Avenue, Box 30270-00100, Nairobi, Kenya.
Received: 17 June 2015 Accepted: 27 May 2016
References
1. Mondal SK, Dutta TK. A ten year clinicopathological study of female genital
tuberculosis and impact on fertility. JNMA J Nepal Med Assoc. 2009;48:52–7.
2. Tripathy SN, Tripathy SN. Gynaecological tuberculosis – an update. Indian J
Tuberc. 1998;45:193–7.
3. Bhanothu V, Theophilus JP, Rozati R. Use of endo-ovarian tissue biopsy and
pelvic aspirated fluid for the diagnosis of female genital tuberculosis by
conventional versus molecular methods. PLoS One. 2014;9:e98005.
4. Kulshrestha V, Kriplani A, Agarwal N, Singh UB, Rana T. Genital tuberculosis
among infertile women and fertility outcome after antitubercular therapy.
Int J Gynaecol Obstet. 2011;113:229–34.
5. Huang JYJ, Rosenwaks Z. In vitro fertilisation treatment and factors affecting
success. Best Pract Res Clin Obstet Gynaecol. 2012;26:777–88.
6. Kumar P, Shah NP, Singhal A, Chauhan DS, Katoch VM, Mittal S, et al.
Association of Tuberculous Endometritis with Infertility and Other
Gynecological Complaints of Women in India. J Clin Microbiol. 2008;46:4068.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Mariara et al. Journal of Medical Case Reports  (2016) 10:168 Page 4 of 4
